What is Beam Therapeutics Inc.'s market cap?

Beam Therapeutics Inc. (BEAM) has a market capitalization of $2.48B as of null. Market cap is calculated by multiplying the current stock price by the total shares outstanding.

What is BEAM's P/E ratio?

BEAM has a trailing P/E ratio of — and a forward P/E of -5.06 based on next-twelve-months earnings estimates.

What is the analyst price target for BEAM?

Wall Street analysts have a consensus price target of $52.15 for BEAM. View the full analyst breakdown on BriMindInvest.

What is BEAM's BriMind AI Score?

BEAM has a BriMind AI Score of 31/100 as of null. The score synthesizes valuation, growth momentum, profitability, and analyst sentiment into a single composite rating. Scores above 70 indicate attractive risk/reward; below 40 suggests caution.

How has BEAM stock performed over the past year?

BEAM has gained 12.7% over the past 52 weeks as of null. The 50-day moving average is $28.61 and the 200-day moving average is $28.60.

What is BEAM's revenue growth?

Beam Therapeutics Inc. (BEAM) reported year-over-year revenue growth of -94.2%, with trailing twelve-month revenue of $156.0M.

What are BEAM's profit margins?

Beam Therapeutics Inc. has a net profit margin of -55.4% and an operating margin of -25827.1%.

How much debt does Beam Therapeutics Inc. carry?

Beam Therapeutics Inc. (BEAM) has a debt-to-equity ratio of 0.23.

What is base editing and how does it differ from CRISPR-Cas9?

Conventional CRISPR-Cas9 cuts both strands of DNA at a target site and relies on the cell's repair machinery, which can occasionally produce unintended insertions, deletions, or larger rearrangements. Base editing instead uses a modified system to chemically convert one DNA base directly into another — for example C to T — without making a double-strand break. It is a more surgical change, which in principle reduces the risk of unintended structural consequences at the edit site.

Why does avoiding double-strand breaks matter?

Because double-strand breaks are the most dangerous thing you can do to a chromosome. Cellular repair is imperfect and can produce deletions or translocations, some of which carry theoretical cancer risk. For a one-time permanent edit in a patient who may live for decades afterwards, that matters a great deal. If base editing demonstrably reduces this risk, it could enable editing in tissues and indications where regulators would not accept nuclease-based approaches.

Is Beam behind its competitors?

In blood disorders, yes — an approved CRISPR therapy for sickle cell disease already exists, so Beam is developing into a market with an established competitor rather than creating a category. Its argument must be a better product: less toxic conditioning, better efficacy, or a cleaner safety profile. The in vivo liver programmes are a different competitive picture, where base editing's precision may matter more and no editing therapy is yet established.

What should investors watch at Beam?

Clinical data from lead programmes is the core signal, with particular attention to whether the precision advantage shows up as a measurable safety or efficacy benefit rather than remaining theoretical. Progress in the in vivo liver programmes, where differentiation may be strongest. Cash position and burn, since the company is pre-revenue with a broad pipeline. Collaboration announcements for funding and validation. And competitive clinical results in the same indications.

Beam Therapeutics Inc. (BEAM) Stock Analysis 2026

HealthcareBase Editing Therapeutics

BriMind AI Score

Proprietary

Weak

Price CAGR

4.9%

1Y Return

-1.7%

Analyst Upside

+101.6%

Rev Growth

-94.2%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

About Beam Therapeutics Inc.

Beam Therapeutics develops medicines using base editing, a refinement of CRISPR that chemically converts one DNA base into another without cutting both strands of the double helix. The thesis is precision: avoiding double-strand breaks should reduce the risk of unintended rearrangements. Lead programmes target sickle cell disease and beta thalassemia, alongside liver-directed in vivo programmes including alpha-1 antitrypsin deficiency.

How Beam Therapeutics Makes Money

Beam is pre-commercial, funded by cash reserves and collaboration agreements. Value creation depends entirely on advancing clinical programmes and demonstrating that base editing delivers a genuine safety or efficacy advantage over nuclease-based editing. Collaborations provide funding and validation, but there is no product revenue, so the balance sheet and clinical milestones are the substance of the investment case.

Beam Therapeutics Revenue & Profitability Breakdown

This chart shows how Beam Therapeutics's revenue flows through to profit. As a financial-sector company, Beam Therapeutics doesn't report a traditional cost-of-revenue/gross-margin split, so the cascade starts from operating expenses and works down to net income — the actual profit shareholders own. A high net margin indicates efficient expense control and capital allocation.

Revenue

$156.0M

Operating Expenses & Cost of Revenue

-$156.0M

Operating Income

$0-25827.1% margin

Tax & Other

-$86.5M

Net Income

-$-86.5M-55.4% margin

Operating Margin

-25827.1%

Net Margin

-55.4%

Key Financial Metrics

Beam Therapeutics Inc. doesn't carry a meaningful trailing P/E right now, generates $-241.8M in free cash flow, runs a debt/equity ratio of 23.17, and converts shareholder equity into profit at a -8.2% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap

$2.48B

P/E (Forward)

-5.06

Price / Book

2.25

Revenue

$156.0M

Revenue Growth

-94.2%

EPS (Trailing)

$-0.69

EPS (Forward)

$-4.74

Gross Margin

-161.9%

Operating Margin

-25827.1%

Net Margin

-55.4%

Return on Equity

-8.2%

Return on Assets

-17.0%

Free Cash Flow

$-241.8M

Debt / Equity

23.17

Current Ratio

14.57

Quick Ratio

14.25

Beta

2.23

Dividend Yield

None

Payout Ratio

0.0%

Insider Ownership

1.4%

Inst. Ownership

107.8%

Short % Float

38.6%

Book Value / Share

$10.69

Wall Street Analyst Consensus

Wall Street analysts covering Beam Therapeutics Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $52.15. Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$52.15

Technical Price Signals

BEAM is currently in a mixed technical position. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

50-Day MA

$28.61

200-Day MA

$28.60

BEAM Investment Case: Bull vs Bear

BEAM's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Bull Case (Reasons to Buy)

Base editing avoids double-strand DNA breaks, which should mean a lower risk of chromosomal rearrangements than nuclease editing.
A precision advantage could allow editing in tissues and indications where nuclease-based approaches carry unacceptable risk.
Programmes span both ex vivo blood disorders and in vivo liver targets, diversifying technical and clinical risk.
A solid cash position funds development through multiple clinical milestones without immediate financing need.

Bear Case (Key Risks)

Beam is behind competitors in blood disorders, where an approved gene-editing therapy already exists and is being commercialised.
The theoretical precision advantage still requires clinical demonstration — safety benefits are hard to prove in modestly sized trials.
Pre-revenue status with significant burn means eventual dilution is likely unless partnerships expand substantially.
Ex vivo programmes still require conditioning chemotherapy, so they inherit the same scaling constraints as existing therapies.

What to Watch: BEAM Key Metrics

Lead programme clinical data

In vivo programme progress

Cash position and burn rate

Collaboration revenue

Safety profile versus nuclease editing

BEAM Stock — Frequently Asked Questions

Compare BEAM with Peers

BEAM vs CRSPBeam Therapeutics vs CRISPR Therapeutics — Base Editing

BEAM vs NTLABeam Therapeutics vs Intellia — Base Editing vs In Vivo

More Healthcare Stock Analysis

In-depth reports on companies operating alongside BEAM — business models, bull and bear cases, and the metrics that matter.

CRSPCRISPR Therapeutics AGGene Editing Therapeutics NTLAIntellia Therapeutics, Inc.In Vivo Gene Editing SRPTSarepta Therapeutics, Inc.Rare Neuromuscular Disease Therapeutics ALNYAlnylam Pharmaceuticals, Inc.RNA Interference Therapeutics INSMInsmed IncorporatedRespiratory & Rare Disease Therapeutics JNJJohnson & JohnsonPharmaceuticals & Medical Devices PRMEPrime Medicine, Inc.Biotechnology INCYIncyte CorporationBiotechnology

Unlock the Full BEAM Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free Trial Browse All Stocks

Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.

← Back to Home · Browse All Stock Analysis